ABCL
Price
$3.73
Change
-$0.07 (-1.84%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
1.13B
47 days until earnings call
ZYME
Price
$12.36
Change
-$0.35 (-2.75%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
861.98M
Interact to see
Advertisement

ABCL vs ZYME

Header iconABCL vs ZYME Comparison
Open Charts ABCL vs ZYMEBanner chart's image
AbCellera Biologics
Price$3.73
Change-$0.07 (-1.84%)
Volume$33.69K
Capitalization1.13B
Zymeworks
Price$12.36
Change-$0.35 (-2.75%)
Volume$18.82K
Capitalization861.98M
ABCL vs ZYME Comparison Chart in %
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. ZYME commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Buy and ZYME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ABCL: $3.80 vs. ZYME: $12.71)
Brand notoriety: ABCL and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 187% vs. ZYME: 69%
Market capitalization -- ABCL: $1.13B vs. ZYME: $861.98M
ABCL [@Biotechnology] is valued at $1.13B. ZYME’s [@Biotechnology] market capitalization is $861.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 6 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 6 bullish, 4 bearish.
  • ZYME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than ZYME.

Price Growth

ABCL (@Biotechnology) experienced а +9.51% price change this week, while ZYME (@Biotechnology) price change was +0.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +32.55%, and the average quarterly price growth was +15.13%.

Reported Earning Dates

ABCL is expected to report earnings on Aug 12, 2025.

ZYME is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.13B) has a higher market cap than ZYME($862M). ABCL YTD gains are higher at: 29.693 vs. ZYME (-13.183). ZYME has higher annual earnings (EBITDA): -95.45M vs. ABCL (-211.2M). ABCL has more cash in the bank: 605M vs. ZYME (265M). ZYME has less debt than ABCL: ZYME (18.5M) vs ABCL (67.8M). ZYME has higher revenues than ABCL: ZYME (93.4M) vs ABCL (23.1M).
ABCLZYMEABCL / ZYME
Capitalization1.13B862M132%
EBITDA-211.2M-95.45M221%
Gain YTD29.693-13.183-225%
P/E RatioN/AN/A-
Revenue23.1M93.4M25%
Total Cash605M265M228%
Total Debt67.8M18.5M366%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
72
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
65
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 23 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STRGX58.93N/A
N/A
Sterling Capital MdCp Relatv Val Instl
NSVAX13.21N/A
N/A
Columbia Small Cap Value II Inst
ACIZX50.74N/A
N/A
Alger Capital Appreciation Instl Z-2
TIBCX29.59-0.03
-0.10%
Thornburg Investment Income Builder C
MOPAX23.91-0.20
-0.83%
NYLI WMC Small Companies Class A

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+3.26%
CRSP - ABCL
62%
Loosely correlated
+1.88%
RXRX - ABCL
59%
Loosely correlated
-1.15%
ABSI - ABCL
57%
Loosely correlated
-1.78%
VCYT - ABCL
56%
Loosely correlated
-1.60%
BEAM - ABCL
55%
Loosely correlated
-2.27%
More